Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma

Rituximab resistance has become increasingly common in patients with diffuse large B cell lymphoma (DLBCL). However, the mechanisms involved remain unclear. In this study, we aimed to examine the effect of rituximab on interleukin (IL)-17A and to investigate the role of IL-17A in rituximab resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Weijie, Xu, Xin, Zhu, Zhigang, Yang, Li, Du, Hong, Xia, Zhongjun, Yuan, Zhaohu, Xiong, Huabao, Du, Qinghua, Wei, Yaming, Li, Qingshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873833/
https://www.ncbi.nlm.nih.gov/pubmed/29512700
http://dx.doi.org/10.3892/ijo.2018.4299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873833/
https://www.ncbi.nlm.nih.gov/pubmed/29512700
http://dx.doi.org/10.3892/ijo.2018.4299

Ejemplares similares